Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 8/20 | 0.41 |
| ▸ | CDK8 | P49336 | 8/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408285 | 0.90 | CCNC (0.51) | CCNCCDK8TBXAS1CDK19PKM | |
| SCHEMBL9756945 | 0.83 | CCNC (0.45) | CCNCCDK8TBXAS1ALDH1A1KDM4E | |
| SCHEMBL9756944 | 0.83 | CCNC (0.45) | CCNCCDK8TBXAS1ALDH1A1KDM4E | |
| SCHEMBL851868 | 0.81 | PTGER3 (0.55) | TBXAS1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL851869 | 0.81 | PTGER3 (0.55) | TBXAS1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL8580162 | 0.77 | PKM (0.43) | TBXAS1SMN1; SMN2TDP1PKM | |
| SCHEMBL21855464 | 0.75 | PKM (0.41) | TBXAS1SMN1; SMN2TDP1PKM | |
| SCHEMBL5894021 | 0.75 | AOC1 (0.47) | TBXAS1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL5800280 | 0.75 | NAMPT (0.51) | TBXAS1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL3587236 | 0.74 | PKM (0.43) | TBXAS1ALDH1A1SMN1; SMN2TDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CCNC 3198/4885CDK8 1843/4885TBXAS1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.